The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells

Po An Tai, Yen Lin Liu, Ya Ting Wen, Chien Min Lin, Thanh Tuan Huynh, Michael Hsiao, Alexander T.H. Wu, Li Wei

研究成果: 雜誌貢獻文章

摘要

Glioblastoma multiforme represents one of the deadliest brain tumor types, manifested by a high rate of recurrence and poor prognosis. The presence of glioma stem cells (GSCs) can repopulate the tumor posttreatment and resist therapeutics. A better understanding of GSC biology is essential for developing more effective interventions. We established a CD133 promoter-driven dual reporter, expressing green fluorescent protein (GFP) and firefly luciferase (CD133-LG), capable for in vitro and in vivo imaging of CD133+ GSCs. We first demonstrated the reporter enabled in vitro analyses of GSCs. DBTRG-05MG (Denver Brain Tumor Research Group 05) carrying CD133-LG (DBTRG-05MG-CD133-LG) system reported increased GFP/luciferase activities in neurospheres. Additionally, we identified and isolated CD133+/GFP+ cells with increased tumorigenic properties, stemness markers, Notch1, β-catenin, and Bruton’s tyrosine kinase (Btk). Furthermore, prolonged temozolomide (TMZ) treatment enriched GSCs (reflected by increased percentage of CD133+ cells). Subsequently, Btk inhibitor, ibrutinib, suppressed GSC generation and stemness markers. Finally, we demonstrated real-time evaluation of anti-GSC function of ibrutinib in vivo with TMZ-enriched GSCs. Tumorigenesis was noninvasively monitored by bioluminescence imaging and mice that received ibrutinib showed a significantly lower tumor burden, indicating ibrutinib as a potential GSC inhibitor. In conclusion, we established a dual optical imaging system which enables the identification of CD133+ GSCs and screening for anti-GSC drugs.

原文英語
期刊Molecular Imaging
18
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

Optical Devices
stem cells
Optical Imaging
Stem cells
Glioma
Imaging systems
Stem Cells
temozolomide
Tumors
tumors
Green Fluorescent Proteins
tyrosine
proteins
Proteins
Brain Neoplasms
markers
inhibitors
brain
Brain
fireflies

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics

引用此文

The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells. / Tai, Po An; Liu, Yen Lin; Wen, Ya Ting; Lin, Chien Min; Huynh, Thanh Tuan; Hsiao, Michael; Wu, Alexander T.H.; Wei, Li.

於: Molecular Imaging, 卷 18, 01.01.2019.

研究成果: 雜誌貢獻文章

@article{d299cdc45c0942d990a6bfa0920ddd94,
title = "The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells",
abstract = "Glioblastoma multiforme represents one of the deadliest brain tumor types, manifested by a high rate of recurrence and poor prognosis. The presence of glioma stem cells (GSCs) can repopulate the tumor posttreatment and resist therapeutics. A better understanding of GSC biology is essential for developing more effective interventions. We established a CD133 promoter-driven dual reporter, expressing green fluorescent protein (GFP) and firefly luciferase (CD133-LG), capable for in vitro and in vivo imaging of CD133+ GSCs. We first demonstrated the reporter enabled in vitro analyses of GSCs. DBTRG-05MG (Denver Brain Tumor Research Group 05) carrying CD133-LG (DBTRG-05MG-CD133-LG) system reported increased GFP/luciferase activities in neurospheres. Additionally, we identified and isolated CD133+/GFP+ cells with increased tumorigenic properties, stemness markers, Notch1, β-catenin, and Bruton’s tyrosine kinase (Btk). Furthermore, prolonged temozolomide (TMZ) treatment enriched GSCs (reflected by increased percentage of CD133+ cells). Subsequently, Btk inhibitor, ibrutinib, suppressed GSC generation and stemness markers. Finally, we demonstrated real-time evaluation of anti-GSC function of ibrutinib in vivo with TMZ-enriched GSCs. Tumorigenesis was noninvasively monitored by bioluminescence imaging and mice that received ibrutinib showed a significantly lower tumor burden, indicating ibrutinib as a potential GSC inhibitor. In conclusion, we established a dual optical imaging system which enables the identification of CD133+ GSCs and screening for anti-GSC drugs.",
keywords = "Btk inhibitor, CD133, dual optical imaging system, glioma stem cells (GSCs), temozolomide resistance",
author = "Tai, {Po An} and Liu, {Yen Lin} and Wen, {Ya Ting} and Lin, {Chien Min} and Huynh, {Thanh Tuan} and Michael Hsiao and Wu, {Alexander T.H.} and Li Wei",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1536012119870899",
language = "English",
volume = "18",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",

}

TY - JOUR

T1 - The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells

AU - Tai, Po An

AU - Liu, Yen Lin

AU - Wen, Ya Ting

AU - Lin, Chien Min

AU - Huynh, Thanh Tuan

AU - Hsiao, Michael

AU - Wu, Alexander T.H.

AU - Wei, Li

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glioblastoma multiforme represents one of the deadliest brain tumor types, manifested by a high rate of recurrence and poor prognosis. The presence of glioma stem cells (GSCs) can repopulate the tumor posttreatment and resist therapeutics. A better understanding of GSC biology is essential for developing more effective interventions. We established a CD133 promoter-driven dual reporter, expressing green fluorescent protein (GFP) and firefly luciferase (CD133-LG), capable for in vitro and in vivo imaging of CD133+ GSCs. We first demonstrated the reporter enabled in vitro analyses of GSCs. DBTRG-05MG (Denver Brain Tumor Research Group 05) carrying CD133-LG (DBTRG-05MG-CD133-LG) system reported increased GFP/luciferase activities in neurospheres. Additionally, we identified and isolated CD133+/GFP+ cells with increased tumorigenic properties, stemness markers, Notch1, β-catenin, and Bruton’s tyrosine kinase (Btk). Furthermore, prolonged temozolomide (TMZ) treatment enriched GSCs (reflected by increased percentage of CD133+ cells). Subsequently, Btk inhibitor, ibrutinib, suppressed GSC generation and stemness markers. Finally, we demonstrated real-time evaluation of anti-GSC function of ibrutinib in vivo with TMZ-enriched GSCs. Tumorigenesis was noninvasively monitored by bioluminescence imaging and mice that received ibrutinib showed a significantly lower tumor burden, indicating ibrutinib as a potential GSC inhibitor. In conclusion, we established a dual optical imaging system which enables the identification of CD133+ GSCs and screening for anti-GSC drugs.

AB - Glioblastoma multiforme represents one of the deadliest brain tumor types, manifested by a high rate of recurrence and poor prognosis. The presence of glioma stem cells (GSCs) can repopulate the tumor posttreatment and resist therapeutics. A better understanding of GSC biology is essential for developing more effective interventions. We established a CD133 promoter-driven dual reporter, expressing green fluorescent protein (GFP) and firefly luciferase (CD133-LG), capable for in vitro and in vivo imaging of CD133+ GSCs. We first demonstrated the reporter enabled in vitro analyses of GSCs. DBTRG-05MG (Denver Brain Tumor Research Group 05) carrying CD133-LG (DBTRG-05MG-CD133-LG) system reported increased GFP/luciferase activities in neurospheres. Additionally, we identified and isolated CD133+/GFP+ cells with increased tumorigenic properties, stemness markers, Notch1, β-catenin, and Bruton’s tyrosine kinase (Btk). Furthermore, prolonged temozolomide (TMZ) treatment enriched GSCs (reflected by increased percentage of CD133+ cells). Subsequently, Btk inhibitor, ibrutinib, suppressed GSC generation and stemness markers. Finally, we demonstrated real-time evaluation of anti-GSC function of ibrutinib in vivo with TMZ-enriched GSCs. Tumorigenesis was noninvasively monitored by bioluminescence imaging and mice that received ibrutinib showed a significantly lower tumor burden, indicating ibrutinib as a potential GSC inhibitor. In conclusion, we established a dual optical imaging system which enables the identification of CD133+ GSCs and screening for anti-GSC drugs.

KW - Btk inhibitor

KW - CD133

KW - dual optical imaging system

KW - glioma stem cells (GSCs)

KW - temozolomide resistance

UR - http://www.scopus.com/inward/record.url?scp=85071740726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071740726&partnerID=8YFLogxK

U2 - 10.1177/1536012119870899

DO - 10.1177/1536012119870899

M3 - Article

C2 - 31478435

AN - SCOPUS:85071740726

VL - 18

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

ER -